Sesiclenegene cosaparvovec

柯哌斯奈基

Report date: 2026/05/14 20:00:28

Base Information

Drug NameSesiclenegene cosaparvovec
Drug Alias NamescAAV9.CB.CLN6scAAV-9.CB.CLN-6AT-GTX-501
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector
Mechanisms of ActionCeroid-lipofuscinosis neuronal protein 6 expression stimulants
TargetsCeroid-lipofuscinosis neuronal protein 6
Therapy Area/IndicationsNeuronal Ceroid-Lipofuscinoses
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAmicus Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San Diego
Inactive CompaniesAmicus Therapeutics Inc
Active IndicationsNeuronal Ceroid-Lipofuscinoses
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A